FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:88-89 July 3, 2003 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Pitt, B. PubMed Citation

To the Editor: The results of the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), reported by Pitt et al. (April 3 issue),¹ yield evidence of a benefit from selective aldosterone blockade with eplerenone in patients with acute myocardial infarction complicated by left ventricular dysfunction, beyond the benefit achieved with optimal medical therapy including angiotensin-converting–enzyme (ACE) inhibitors and beta-blockers. In patients with severe heart failure, aldosterone blockade with spironolactone has previously been demonstrated to provide meaningful reductions in morbidity and mortality as well.² One point of contention is that the authors began randomization in the EPHESUS trial . . . [Full Text of this Article]

This article has been cited by other articles:

• Stecker, E. C., McAnulty, J. H. (2005). Letter Regarding Article by Weintraub et al, "Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure". Circulation 112: e74-e74 [Full Text]